BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 9014971)

  • 1. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
    Rouleau JL; Packer M; Moyé L; de Champlain J; Bichet D; Klein M; Rouleau JR; Sussex B; Arnold JM; Sestier F
    J Am Coll Cardiol; 1994 Sep; 24(3):583-91. PubMed ID: 7915733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
    Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
    Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
    Lamas GA; Flaker GC; Mitchell G; Smith SC; Gersh BJ; Wun CC; Moyé L; Rouleau JL; Rutherford JD; Pfeffer MA
    Circulation; 1995 Sep; 92(5):1101-9. PubMed ID: 7648653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-adrenergic blocking agents or angiotensin-converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction.
    O'Rourke RA
    J Am Coll Cardiol; 1997 Feb; 29(2):237-9. PubMed ID: 9014972
    [No Abstract]   [Full Text] [Related]  

  • 6. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
    Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M
    Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
    Shekelle PG; Rich MW; Morton SC; Atkinson CS; Tu W; Maglione M; Rhodes S; Barrett M; Fonarow GC; Greenberg B; Heidenreich PA; Knabel T; Konstam MA; Steimle A; Warner Stevenson L
    J Am Coll Cardiol; 2003 May; 41(9):1529-38. PubMed ID: 12742294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
    Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
    J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
    Reiffel JA; ;
    Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
    Coletta C; Ricci R; Ceci V; Seccareccia F; Rulli F; Mazzuca V; Putini RL; Salustri A; Bottero G; Pasquale M
    G Ital Cardiol; 1999 Feb; 29(2):115-24; discussion 125-9. PubMed ID: 10088066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance.
    Kyriakidis M; Antonopoulos A; Georgiou E; Santas P; Bakirtzis C; Toutouzas P
    Eur Heart J; 1996 Jun; 17(6):864-73. PubMed ID: 8781825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.